𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study

✍ Scribed by Moroni, Gabriella (author);Gallelli, Beniamina (author);Sinico, Renato Alberto (author);Romano, Giulio (author);Sinigaglia, Luigi (author);Messa, Piergiorgio (author)

Book ID
121813619
Publisher
BMJ Publishing Group
Year
2012
Tongue
English
Weight
78 KB
Volume
71
Category
Article
ISSN
0003-4967

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Histopathologic and clinical outcome of
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
✍ Iva Gunnarsson; Birgitta Sundelin; Thorunn JΓ³nsdΓ³ttir; Stefan H. Jacobson; Elisa πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab is a monoclonal antibody directed against the CD20 marker of B cells. Because of its ability to deplete B lymphocytes, it has been suggested that the drug could be of benefit in B cell–dependent diseases, including systemic lupus erythematosus (SLE). The purpose